| Literature DB >> 29479282 |
Abstract
Invasive meningococcal disease (IMD) is serious, often resulting in fulminant sepsis or meningitis. IMD in Canada is primarily attributable to serogroups B and C. There are routine programs for serogroup C vaccine at 12 months of age, with some jurisdictions routinely providing additional earlier doses. Adolescents routinely receive a booster dose of serogroup C vaccine or of a quadrivalent (serogroups A, C, W and Y) vaccine. Serogroup B vaccines are not recommended for routine use pending further data on the efficacy and duration of protection from the available vaccine. However, children at increased risk for IMD should start immunization for serogroups B and C as soon as possible, assuming that they are at least 2 months of age.Entities:
Keywords: IMD; Meningitis; Sepsis; Vaccine
Year: 2018 PMID: 29479282 PMCID: PMC5814812 DOI: 10.1093/pch/pxx162
Source DB: PubMed Journal: Paediatr Child Health ISSN: 1205-7088 Impact factor: 2.253